Mangoceuticals, or MangoRx, announced the migration to its newly developed DEA-approved telemedicine operating system. This milestone marks a significant advancement in MangoRx’s capabilities, reinforcing its commitment to innovation and superior patient care. The new operating system, authorized by the DEA and integrated with Surescripts, allows MangoRx’s third-party doctor network to prescribe and offer controlled substances. This approval not only distinguishes MangoRx in the Direct-to-Consumer telemedicine space but also validates the Company’s cutting-edge technology and regulatory compliance. The company anticipates making these products available to patients before the end of Q3.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MGRX:
- MangoRx Completes Migration to DEA-Approved Telemedicine Platform, Accelerating Timeline of Oral Dissolvable GLP-1 Weight Loss Treatments Featuring Semaglutide and Tirzepatide
- MangoRx Initiates Efficacy Studies on its Patented Respiratory Illness Prevention Technology
- MangoRx initiates efficacy studies on patented respiratory illness prevention
- Mangoceuticals CEO Jacob Cohen Featured on Benzinga All-Access
- Mangoceuticals secures FDA approval for HIPAA-compliant operating system